[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ: Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer; 2005 Feb 15;103(4):802-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
  • BACKGROUND: Anaplastic oligodendroglioma (OD) tumors, especially those with the combined loss of the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q), are sensitive to chemotherapy.
  • Only limited data are available on the role of chemotherapy in low-grade OD.
  • The authors retrospectively studied the outcome of the procarbazine, lomustine, and vincristine (PCV) chemotherapy regimen in a group of 16 patients with newly diagnosed OD and 5 patients with recurrent low-grade OD.
  • METHODS: Two groups of patients were studied: newly diagnosed patients with large OD and mixed oligoastrocytomas (OA) and patients with recurrent OD and OA after radiotherapy who still showed nonenhancing tumors.
  • Treatment consisted of standard PCV chemotherapy.
  • In the newly diagnosed and responding patients, radiotherapy was withheld until the time of disease recurrence.
  • The median time to disease progression in this group was >24 months.
  • Only one of these patients experienced disease progression while receiving chemotherapy.
  • CONCLUSIONS: Newly diagnosed patients with OD tumors, with or without loss of 1p/19q, responded to PCV chemotherapy.
  • Up-front chemotherapy may be indicated especially for patients with large tumors.
  • A Phase III trial should be initiated to compare radiotherapy with chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lomustine / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction. Procarbazine / therapeutic use. Retrospective Studies. Tumor Suppressor Protein p53 / genetics. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • (PMID = 15637687.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


2. Levin VA, Lamborn K, Wara W, Davis R, Edwards M, Rabbitt J, Malec M, Prados MD: Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children. Neuro Oncol; 2000 01;2(1):22-8
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
  • We conducted a single-arm phase II study to evaluate the efficacy and safety of radiotherapy combined with 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine (TPDCV) chemotherapy for treating malignant astrocytoma in children and anaplastic ependymoma in patients of all ages.
  • Between 1984 and 1992, 42 patients who had malignant astrocytomas (glioblastomas multiforme, anaplastic astrocytomas, or mixed anaplastic oligoastrocytomas) were treated with TPDCV chemotherapy and radiation therapy.
  • Cranial radiation averaged 58 Gy.
  • TPDCV chemotherapy was given for 1 year or until progression.
  • Between 1989 and 1991, 17 patients with malignant ependymoma were treated with TPDCV chemotherapy and craniospinal radiation.
  • Radiation was given at an average dose of 54 Gy to the tumor, 28 Gy to the whole brain, and 31 Gy to the spinal axis.
  • TPDCV chemotherapy was given for 1 year or until tumor progressed.
  • Of the patients with glioblastoma multiforme, 13 of 17 died; the median time to progression was 49 weeks, and median survival was 85 weeks.
  • Of the patients with nonglioblastoma malignant astrocytoma, 14 of 25 died; the median time to progression was 224 weeks.
  • For the patients with ependymoma, 11 of 17 died with a median time to progression of 141 weeks.
  • Nine patients died with a median survival of 183 weeks.
  • The combination of TPDCV and radiotherapy has activity against childhood anaplastic astrocytoma, glioblastoma multiforme, and anaplastic ependymoma.
  • The results of this study for children with glioblastoma were comparable to results in the literature, while the results for children with anaplastic astrocytoma appeared better than most reports.
  • The combination of TPDCV chemotherapy and radiation therapy for anaplastic ependymomas appears to be active and at least as good as published reports using radiation therapy alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioma / drug therapy. Glioma / radiotherapy. Lomustine / therapeutic use. Mitolactol / therapeutic use. Procarbazine / therapeutic use. Thioguanine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11302250.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA13525
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; FTK8U1GZNX / Thioguanine; LJ2P1SIK8Y / Mitolactol; TPDCV protocol
  • [Other-IDs] NLM/ PMC1920700
  •  go-up   go-down


3. Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M: Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol; 2009 Apr;11(2):167-75
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
  • The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA).
  • The primary end point was the response rate during the 6-month, pre-RT chemotherapy.
  • Tumor tissue was analyzed for the presence of chromosomal deletions on 1p and 19q and for MGMT-promoter methylation.
  • The objective response rate was 32% (6% [complete response, CR], 26% [partial response PR]), and the rate of progression during pre-RT chemotherapy was 10%.
  • Twenty-two patients completed concurrent chemotherapy and RT.
  • There were no grade 4 nonhematological toxicities during the concurrent chemotherapy and RT.
  • In conclusion, the rate of progression of 10% during pre-RT temozolomide chemotherapy for newly diagnosed AO and MAO compared favorably with prior experience with pre-RT PCV chemotherapy (20% in RTOG 9402).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / therapy. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dose Fractionation. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Promoter Regions, Genetic. Survival Rate. Treatment Outcome. Tumor Suppressor Proteins / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rev. 1997 Jan;23(1):35-61 [9189180.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30 [11020580.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4689-92 [11406538.001]
  • [Cites] Neurology. 2001 Jul 24;57(2):340-2 [11468326.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):267-73 [12675321.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):271-8 [14558604.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4363-7 [9766665.001]
  • (PMID = 18779504.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2718988
  •  go-up   go-down


Advertisement
4. Jenkins RB, Curran W, Scott CB, Cairncross G: Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Am J Clin Oncol; 2001 Oct;24(5):506-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group.
  • Radiation Therapy Oncology Group (RTOG) trial 94-02 is designed to compare the effectiveness of radiation therapy alone with radiation therapy plus procarbazine, lomustine, and vincristine (PCV) chemotherapy in patients with anaplastic oligodendrogliomas and mixed oligoastrocytomas.
  • This prospectively collected, randomly treated, prospectively followed cohort is the ideal set of patients to validate the observation that anaplastic oligodendrogliomas with 1p and 19q deletions have a prolonged survival and a better response to chemotherapy.
  • Also demonstrated is that the incidence of 1p and 19q deletions in this pilot series of anaplastic oligodendrogliomas and mixed oligoastrocytomas is similar to that reported in previous studies.
  • When the clinical follow-up on this prospective trial is mature and the deletion studies have been completed, the authors should be able to determine whether 1p and 19q deletions predict a prolonged survival and/or responsiveness to PCV chemotherapy plus radiation in patients with anaplastic oligodendrogliomas and mixed oligoastrocytomas.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Humans. In Situ Hybridization, Fluorescence. Pilot Projects. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11586105.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA85779
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


5. Hussein MR, Baidas S: Advances in diagnosis and management of oligodendroglioma. Expert Rev Anticancer Ther; 2002 Oct;2(5):520-8
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent clinical trials have shown that oligodendrogliomas are sensitive to PCV chemotherapy with 60-65% of patients responding and median response duration of 1-1.5 years.
  • The response rate in mixed oligoastrocytomas may be slightly less but is still better than that of pure astrocytic tumors.
  • [MeSH-major] Oligodendroglioma / diagnosis. Oligodendroglioma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Cytogenetics. Humans. Prognosis. Radiotherapy / trends. Vindesine / therapeutic use

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12382520.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine; PCV regimen
  • [Number-of-references] 94
  •  go-up   go-down


6. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol; 2000 Feb;18(3):636-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
  • PURPOSE: A recent report suggests that alterations of chromosome arms 1p and 19q are associated with chemotherapeutic response and overall survival in anaplastic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy.
  • PATIENTS AND METHODS: Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected as part of an ongoing prospective investigation of CNS tumors.
  • This favorable association was not evident in patients with astrocytoma or mixed oligoastrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Central Nervous System Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10653879.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA50905; United States / NCI NIH HHS / CA / CA50910; United States / NCI NIH HHS / CA / CA64928
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


7. Oshiro S, Tsugu H, Komatsu F, Ohmura T, Ohta M, Sakamoto S, Fukushima T, Inoue T: Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res; 2009 Mar;29(3):911-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of temozolomide treatment in patients with high-grade glioma.
  • BACKGROUND: Numerous studies have reported the clinical efficacy of temozolomide (TMZ) treatment for high-grade glioma, but information on Japanese populations has been limited.
  • This study assessed the safety and early outcomes of TMZ treatment, with or without combination therapy.
  • PATIENTS AND METHODS: The subjects comprised ten patients with high-grade glioma [glioblastoma multiforme (GBM), n=3, gliosarcoma (GS), n=1, anaplastic oligodendroglioma (AO), n=3, anaplastic mixed oligoastrocytoma (AOA), n=1, and anaplastic ependymoma (AE), n=2].
  • All the patients were initially treated with conventional radiotherapy following surgical resection with or without adjuvant chemotherapy.
  • As second- or third-line chemotherapy, patients received TMZ for recurrence or tumor progression.
  • As combination therapy, the local administration of tumor necrosis factor-alpha and the addition of carboplatin and etoposide were included for three patients during the course of oral TMZ treatment.
  • RESULTS: Partial response (PR) to TMZ therapy was achieved by four out of the ten patients (objective response rate, 40%), while three patients displayed stable disease (SD) and three showed disease progression (PD).
  • One of the patients receiving combination therapy has continued to show shrinkage of the relapsed tumor.
  • Despite prior radio- and chemotherapy, most patients experienced only grade 1-2 hematotoxicity that was well-controlled by conservative therapy.
  • CONCLUSION: TMZ chemotherapy is effective for the treatment of high-grade glioma in some patients without serious toxicity.
  • Assessing the true efficacy of TMZ will require a larger study with comparison of long-term outcomes between other agents or combined therapeutic modalities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Treatment Outcome. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414327.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


8. van den Bent M, Chinot OL, Cairncross JG: Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro Oncol; 2003 04;5(2):128-38
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent developments in the molecular characterization and treatment of oligodendroglial tumors.
  • Although many patients with oligodendrogliomas (ODs) and oligoastrocytomas (OAs) benefit from a combination of surgery and adjuvant radiotherapy, most patients eventually experience recurrence of their disease.
  • These initial findings have prompted further study of chemotherapy in treating ODs and mixed OAs.
  • Advances in molecular genetic analysis have led to improvements in predicting response to chemotherapy and prognosis for ODs, OAs, and astrocytomas.
  • Pure ODs are more chemosensitive than mixed ODs.
  • Therefore, genetic analysis is likely to be key in determining appropriate treatment.
  • The most common first-line chemotherapy for patients with OD is a procarbazine, lomustine, and vincristine (PCV) combination regimen.
  • Therefore, other chemotherapy agents and regimens have been investigated.
  • Temozolomide is approved in the United States for the treatment of recurrent anaplastic astrocytomas and in Europe for any recurrent high-grade gliomas.
  • Initial reports suggest that temozolomide is effective in treating ODs as first- and second-line chemotherapy.
  • [MeSH-major] Astrocytoma / drug therapy. Clinical Trials as Topic / trends. Dacarbazine / analogs & derivatives. Oligodendroglioma / drug therapy

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12672285.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  • [Number-of-references] 120
  • [Other-IDs] NLM/ PMC1920673
  •  go-up   go-down


9. Mason WP: Progress in clinical neurosciences: Advances in the management of low-grade gliomas. Can J Neurol Sci; 2005 Feb;32(1):18-26
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many aspects of the treatment of low-grade gliomas are debated, including the optimal timing of surgery and radiotherapy, the benefit of extensive surgery, and the impact of these variables on the natural history of these indolent and generally incurable tumours.
  • The recognition that as many as two thirds of low-grade gliomas have oligodendroglial features, advances in molecular diagnostics making accurate pathologic diagnosis of oligodendroglial tumours possible, and the established chemosensitivity of malignant oligodendrogliomas, have raised new issues surrounding the potential value of chemotherapy for low-grade gliomas.
  • This review will be restricted to low-grade diffuse astrocytomas, oligodendrogliomas, and low-grade mixed oligoastrocytomas in adults, and provide evidence-based guidelines for the management of these tumours, including the emerging role of chemotherapy as initial treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825542.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 74
  •  go-up   go-down


10. Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G: Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol; 2003 Feb;61(3):267-73
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this IRB-approved retrospective study, we analyzed the efficacy of temozolomide on World Health Organization Grade II and III oligodendrogliomas, as well as mixed oligoastrocytomas, to determine if a correlation exists between the tumors' 1p status and control of growth by this new oral agent.
  • Chromosome 1p status was significantly associated with response to treatment using temozolomide.
  • While nine of 10 patients (90%) with 1p loss responded to temozolomide, only two of six patients (33%) with 1p intact benefited from this treatment (p = 0.04).
  • Gender, age, and tumor grade were similarly not correlated with response to chemotherapy.
  • This report is the first to find that patients harboring oligodendrogliomas with 1p loss are more likely to be sensitive to treatment with temozolomide than those that retain this chromosomal element.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Oligodendroglioma / drug therapy. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Data Interpretation, Statistical. Female. Humans. Loss of Heterozygosity / drug effects. Loss of Heterozygosity / genetics. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] J Neurooncol. 1999 Jun;43(2):137-42 [10533725.001]
  • [Cites] Neurology. 2001 Jul 24;57(2):340-2 [11468326.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1809-13 [8625052.001]
  • [Cites] J Neurosurg. 1992 Mar;76(3):428-34 [1738022.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):61-78 [9210053.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1458-66 [6766802.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Arch Neurol. 1989 Nov;46(11):1238-9 [2818260.001]
  • [Cites] Neurosurgery. 1994 Jun;34(6):959-66; discussion 966 [8084406.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1018-34; discussion 1034-5 [7885546.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2236-41 [9038604.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] Br J Cancer. 1992 Feb;65(2):287-91 [1739631.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] Ann Neurol. 1986 Jan;19(1):15-21 [3947035.001]
  • [Cites] Int J Cancer. 1995 Jun 22;64(3):207-10 [7622310.001]
  • [Cites] Oncology (Williston Park). 1987 Nov;1(9):29-36, 40-1 [3079493.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Can J Neurol Sci. 1997 Nov;24(4):313-9 [9398978.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):205-11 [10359140.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]
  • [Cites] Eur J Cancer. 1993;29A(7):940-2 [8499146.001]
  • [Cites] J Neurosurg. 1992 May;76(5):741-5 [1564535.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):1107-13 [8780550.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]
  • [Cites] Radiology. 1993 Feb;186(2):569-72 [8421767.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):78-82 [1641113.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Clin Cancer Res. 1997 Jul;3(7):1093-100 [9815788.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1345-52 [3545437.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 13):13-8 [11550134.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] Neurosurgery. 1994 Nov;35(5):817-20; discussion 820-1 [7838328.001]
  • (PMID = 12675321.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


11. van den Bent MJ: Chemotherapy of oligodendroglial tumours: current developments. Forum (Genova); 2000 Apr-Jun;10(2):108-18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy of oligodendroglial tumours: current developments.
  • Oligodendroglioma (ODG) constitute a specific type of gliomas, with a better prognosis than astrocytic tumours of similar grade.
  • No clear criteria exist to differentiate astrocytoma from ODG, leading to a significant inter-observer variation in the diagnosis of ODG.
  • Recent clinical trials have shown that ODG are sensitive to chemotherapy with 60-65% of patients responding, with a median response duration of 1-1.5 years.
  • This holds for both low and high-grade ODG; the response rate in mixed oligoastrocytomas may be slightly less but is still better than that of pure astrocytic tumours.
  • There is a strong correlation between a favourable response to chemotherapy and the presence of 1p36 and 19q13.3 lesions, suggesting this may be used to select patients for treatment.
  • The presence of 1p lesions is also related to a longer progression free survival after radiation therapy, implicating that the assessment of the presence of 1p lesions is an important prognostic tool for ODG.
  • Ongoing trials are investigating whether adjuvant chemotherapy after surgery and radiation therapy provides better survival and quality of life in newly-diagnosed anaplastic ODG.
  • However, even patients with a good response to chemotherapy will ultimately relapse.
  • This calls for improvement of the chemotherapy schedules and for improvement of second line chemotherapy.
  • In the near future molecular analysis may become an important tool to identify tumours that are likely to respond to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Evaluation Studies as Topic. Humans. Lomustine / therapeutic use. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Procarbazine / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10875973.001).
  • [ISSN] 1121-8142
  • [Journal-full-title] Forum (Genoa, Italy)
  • [ISO-abbreviation] Forum (Genova)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] ITALY
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
  • [Number-of-references] 66
  •  go-up   go-down


12. Sarkar A, Pollock BE, Brown PD, Gorman DA: Evaluation of gamma knife radiosurgery in the treatment of oligodendrogliomas and mixed oligodendroastrocytomas. J Neurosurg; 2002 Dec;97(5 Suppl):653-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of gamma knife radiosurgery in the treatment of oligodendrogliomas and mixed oligodendroastrocytomas.
  • OBJECT: Radiosurgery is commonly used for the treatment of patients with glioma.
  • The goal of this study was to evaluate the safety and efficacy of radiosurgery in the management of patients with oligodendrogliomas (ODGs) or mixed oligoastrocytomas (OGAs).
  • METHODS: A retrospective chart review of patients treated between May 1990 and January 2000 identified 18 patients (21 tumors) with either an ODG (10) or a mixed OGA (11) who had undergone radiosurgery.
  • Seventeen patients had undergone prior radiotherapy; 11 were treated with chemotherapy before radiosurgery, and one had undergone a prior linear accelerator-based radiosurgery treatment.
  • The median tumor volume was 8.2 cm3 (range 1.9-47.7 cm3); the median margin dose was 15 Gy (range 12-20 Gy); and the median maximum dose was 32 Gy (range 24-50 Gy).
  • CONCLUSIONS: For patients with oligoastroglial tumors that have failed to respond to conventional therapies, radiosurgery may provide some survival benefit.
  • Further study is needed to determine which subpopulation of these patients will have the best chances of enhanced survival from this treatment.
  • [MeSH-minor] Adult. Aged. Evaluation Studies as Topic. Female. Humans. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12507114.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht ChJ, Allgeier A, Gorlia T, European Organization for Research and Treatment of Cancer Brain Tumor Group: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol; 2003 Jul 1;21(13):2525-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
  • PURPOSE: Oligodendroglial tumors are chemotherapy-sensitive tumors, with two thirds of patients responding to combination chemotherapy with procarbazine, lomustine, and vincristine (PCV).
  • Temozolomide (TMZ), a new alkylating and methylating agent, has demonstrated high response rates in patients with recurrent anaplastic astrocytoma.
  • We investigated TMZ as first-line chemotherapy in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after surgery and radiation therapy.
  • Patients with a recurrence after prior surgery and radiotherapy, and with measurable and enhancing disease on magnetic resonance imaging (MRI) were eligible for this study.
  • The most frequent side effects were hematologic; only one patient discontinued treatment for toxicity.
  • The median time to progression was 10.4 months for all patients and 13.2 months for responding patients.
  • At 12 months from the start of treatment, 40% of patients were still free from progression.
  • CONCLUSION: TMZ provides an excellent response rate with good tolerability in chemotherapy-naive patients with recurrent OD.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / pharmacology. Neoplasm Recurrence, Local / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Disease Progression. Drug Administration Schedule. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12829671.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


14. van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol; 2003 Apr;14(4):599-602
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
  • BACKGROUND: Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding to PCV combination chemotherapy with procarbazine, lomustine (CCNU) and vincristine.
  • Temozolomide (TMZ), a new alkylating and methylating agent has shown high response rates in recurrent anaplastic astrocytoma.
  • We investigated this drug in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after prior PCV chemotherapy and radiation therapy.
  • Eligible patients had a recurrence after prior PCV chemotherapy, with measurable and enhancing disease as shown by magnetic resonance imaging.
  • Twelve of 24 patients [50%, 95% confidence interval (CI) 29% to 71%] evaluable for response to first-line PCV chemotherapy had responded to PCV.
  • One patient discontinued treatment due to toxicity.
  • Median time to progression for responding patients was 8.0 months.
  • After 6 and 12 months from the start of treatment, 29% and 11% of patients, respectively, were still free from progression.
  • CONCLUSIONS: TMZ may be regarded as the preferred second-line treatment in OD after failure of PCV chemotherapy.

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12649108.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


15. Cairncross G, Seiferheld W, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Curran W: An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02. J Clin Oncol; 2004 Jul 15;22(14_suppl):1500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02.
  • : 1500 Background: Anaplastic oligodendrogliomas (AOs) and anaplastic oligoastrocytomas (AOAs) are treated with surgery and RT at diagnosis.
  • Progression-free survival tended to be longer after combined treatment; 2.6 years for PCV plus RT versus 1.9 years for RT (HR 1.34, 95% CI 1.00-1.80; p=0.053).
  • Tissues were available on 206 tumors; 92 (46%) had 1p and 19q loss.
  • Irrespective of treatment, patients whose tumors lacked 1p and 19q lived longer than other patients; median survival not reached versus 2.8 years (HR 0.31, 95% CI 0.20-0.48; p<0.001).
  • Longer follow-up is needed to ascertain treatment-specific outcomes for cases with 1p and 19q loss.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015383.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Franceschi E, Cavallo G, Paioli A, Scopece L, Degli Esposti R, Leonardi E, Spagnolli F, Cremonini AM, Pession A, Crino L: Evaluation of 1p and 19q chromosomal alterations in oligodendroglial neoplasms using microdissection and microsatellite analysis technique and correlations with response to chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):1568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of 1p and 19q chromosomal alterations in oligodendroglial neoplasms using microdissection and microsatellite analysis technique and correlations with response to chemotherapy.
  • METHODS: Patients DNA was extracted from peripheral blood to define the wild type allelic condition, instead tumoral DNA was obtained from laser microdissected cells.
  • RESULTS: At the time of abstract submission we evaluated 21 oligodendroglial tumor adult patients: 4 with oligodendroglioma, 12 with anaplastic oligodendroglioma and 5 with mixed oligoastrocytoma (2 G2 and 3 G3).
  • 16/21 patients were treated with chemotherapy.
  • Further results and correlations with response to radiotherapy and chemotherapy, and differences in 1p and 19q LOH pattern between primary and recurrence will be presented at the meeting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015733.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, Banerjee R, Forsyth P, Rich K, Perry A: Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol; 2004 Apr;63(4):314-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic testing is often performed at the time of recurrence, though it is unclear whether these or other genetic alterations provide useful prognostic information.
  • This increased survival in patients with 1p/19q codeleted tumors remained significant when adjustments were made for age, tumor grade, type of surgical procedure, and treatment with radiation or chemotherapy.
  • Only 1 recurrence showed focal EGFR amplification, while 5 developed 10q deletions, mostly in high-grade mixed oligoastrocytomas lacking 1p/19q deletions.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15099021.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA97247
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


18. Tatter SB: Recurrent malignant glioma in adults. Curr Treat Options Oncol; 2002 Dec;3(6):509-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meaningful palliation is possible for selected patients with recurrent malignant glioma (glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic mixed oligoastrocytoma) using aggressive treatment.
  • Surgical resection with the placement of lomustine-releasing wafers is the only therapy proven in randomized trials to be beneficial for recurrent malignant gliomas.
  • Reoperation may make other treatments more effective by removing treatment-resistant hypoxic cells and thereby prolonging high-quality survival.
  • Combination chemotherapy (including procarbazine and a nitrosourea) provides dramatic benefit for many recurrent anaplastic or aggressively behaving oligodendrogliomas and anaplastic mixed oligoastrocytomas.
  • For other recurrent malignant gliomas, single-agent cytotoxic chemotherapy (eg, intravenous lomustine or platinums, oral carmustine, temozolomide, or procarbazine) appears to provide equivalent results and better quality of life at a lower cost than do the combinations of cytotoxic drugs.
  • Because benefits of available cytotoxic chemotherapy for anaplastic astrocytoma and glioblastoma are small, participation in clinical trials is appropriate for most patients.
  • Reirradiation (using stereotactic or three-dimensional conformal techniques with or without concomitant cytotoxic chemotherapy) as radiation sensitization can prolong high-quality survival in selected patients.
  • Specific examples include radiosurgery with the gamma knife or with linear accelerators, intracavitary radiation with the newly US Food and Drug Administration-approved GliaSite (Proxima Therapeutics, Alpharetta, GA) radiation therapy system, low dose rate permanent-seed brachytherapy, and high dose rate stereotactic brachytherapy.
  • Dexamethasone (used for the shortest time in the lowest effective doses) can provide symptomatic benefits.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Craniotomy. Humans. Neurosurgical Procedures / methods. Radiotherapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1998 Apr;42(4):709-20; discussion 720-3 [9574634.001]
  • [Cites] Nat Med. 2001 Jul;7(7):781-7 [11433341.001]
  • [Cites] J Surg Oncol. 1999 Jul;71(3):167-70 [10404133.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):842-7 [11221866.001]
  • [Cites] Curr Top Microbiol Immunol. 1998;234:97-114 [9670615.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):79-88 [9989517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):541-7 [8655378.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8 [10802351.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):157-61 [10328588.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1005-11 [9719109.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):147-51 [10328586.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1133-9 [11240256.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):776-83; discussion 783-5 [9316038.001]
  • [Cites] Am J Clin Oncol. 1997 Aug;20(4):358-63 [9256889.001]
  • [Cites] Neurosurg Clin N Am. 1999 Apr;10(2):351-8 [10099099.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1354-61 [9396605.001]
  • [Cites] J Neurosurg. 1992 Feb;76(2):179-83 [1730945.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Gene Ther. 2000 May;7(10):859-66 [10845724.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):434-6 [10199331.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):687-92 [10524423.001]
  • [Cites] Nat Med. 1997 Jun;3(6):639-45 [9176490.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):789-93 [10098434.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4 [7731507.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):615-21 [2827052.001]
  • [Cites] Neurosurgery. 1997 Nov;41(5):1039-49; discussion 1049-51 [9361057.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):977-82 [10192343.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):125-32 [9647183.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Neurology. 1980 Feb;30(2):172-7 [6243762.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):3-8 [1572829.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):433-41 [8892469.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):59-64 [10582670.001]
  • [Cites] Semin Surg Oncol. 1997 May-Jun;13(3):157-66 [9143053.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14 ):1788-95 [10974627.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1045-53 [8985026.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1129-39 [2557303.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • (PMID = 12392640.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 47
  •  go-up   go-down


19. Pace A, Vidiri A, Galiè E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM: Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol; 2003 Dec;14(12):1722-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
  • BACKGROUND: The optimal treatment for low-grade glioma (LGG) is still controversial.
  • Recent data indicate a potential influence of chemotherapy on the natural evolution of these tumors, allowing for the deferral of more aggressive therapies.
  • PATIENTS AND METHODS: Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10 mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented clinical and radiological progression.
  • Thirty patients (69.7%) had previously received radiotherapy; 16 (37.2%) had received prior chemotherapy.
  • Median duration of response was 10 months [95% confidence interval (CI) 8-12], with a 76% rate of progression free survival (PFS) at 6 months, and a 39% rate of PFS at 12 months.
  • CONCLUSIONS: The high response rate of 47% (95% CI 31% to 61%) confirms that TMZ chemotherapy is a valid option in the treatment of progressive LGG.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2003 Dec;14(12):1695-6 [14630671.001]
  • (PMID = 14630675.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


20. Chinot O: Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol; 2001 Aug;28(4 Suppl 13):13-8
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for the treatment of oligodendroglial tumors.
  • Oligodendroglial tumors include the highly chemosensitive oligodendroglioma and mixed oligoastrocytoma.
  • Patients with these tumors have a longer median survival and time to disease progression than patients with other brain tumor types, but the range is wide and the disease is inevitably fatal.
  • Because of their chemosensitivity and the potential for radiation toxicity, low-grade oligodendroglioma are increasingly being treated with adjuvant or neoadjuvant chemotherapy before radiation therapy.
  • Approximately two thirds of patients with the more aggressive form (anaplastic oligodendroglioma) have shown substantial response to first-line procarbazine/lomustine/vincristine (PCV) therapy.
  • However, experience with chemotherapy for relapse of disease following PCV therapy is limited.
  • Several small trials have shown the safety and activity of temozolomide (Temodar in the United States, Temodal globally; Schering Corporation, Kenilworth, NJ) in oligodendroglioma, regardless of prior PCV therapy.
  • The only grade (3/4) toxicity with temozolomide treatment was thrombocytopenia, which occurred in < or = 5% of the 382 treatment cycles administered.
  • The encouraging results of ongoing trials with temozolomide suggest the potential for its use as a first-line therapy in this patient population.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Central Nervous System Neoplasms / drug therapy. Dacarbazine / therapeutic use. Oligodendroglioma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Humans. Lomustine / administration & dosage. Procarbazine / administration & dosage. Prognosis. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11550134.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; PCV protocol
  • [Number-of-references] 35
  •  go-up   go-down


21. Sipos L, Vitanovics D, Afra D: Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. Ideggyogy Sz; 2004 Nov 20;57(11-12):394-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
  • In most of the cases of recurrent gliomas chemotherapy is the last choice.
  • The patients received two to 16 courses of chemotherapy.
  • The toxicity, quality of life, response to chemotherapy and survival data were analysed.
  • RESULTS: Out of 75 patients four were excluded following the first treatment due to myelotoxicity, and allergic reactions.
  • The time to progression was 6.8 months and the median survival time 8.75 months for patients with glioblastoma and with malignant astrocytoma or malignant mixed oligoastrocytoma 9.45 and 11.15 months, respectively.
  • CONCLUSIONS: Temozolomide chemotherapy in patients with recurrent malignant astrocytoma and glioblastoma proved to be efficacious and similar good results were achieved as with a nitrosourea based combined chemotherapy.
  • Even in those patients who received previous chemotherapy temozolomide is well tolerated and a relatively long time to progression was achieved in cases of recurrent malignant gliomas.
  • Temozolomide seems to be a promising drug in the chemotherapy of malignant gliomas and can be applied as a second line chemotherapy, as well.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / diagnosis. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Female. Glioblastoma / drug therapy. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662767.001).
  • [ISSN] 0019-1442
  • [Journal-full-title] Ideggyógyászati szemle
  • [ISO-abbreviation] Ideggyogy Sz
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


22. Quon H, Abdulkarim B: Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev; 2008;(2):CD007104
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.
  • However, the impact of adding chemotherapy to surgery and radiotherapy has not been studied.
  • OBJECTIVES: After surgery, to compare radiotherapy (RT) plus chemotherapy versus RT alone (standard of care) in adults with newly diagnosed AO or mixed AOA.
  • Outcomes analyzed include overall survival (OS), progression-free survival (PFS), and treatment toxicity greater than or equal to grade 3.
  • SELECTION CRITERIA: RCTs of adults with AO or mixed AOA comparing surgery plus RT versus surgery plus RT plus chemotherapy were included.
  • No specific chemotherapy regimens were excluded.
  • Based on the differences in patient selection with respect to the definition of AO (2 versus 3 high risk anaplastic features) and sequence of treatment (RT and chemotherapy), the results from the two RCTs were not able to be considered for meta-analysis.
  • MAIN RESULTS: Two RCTs have tested surgery plus RT plus early procarbazine, lomustine, and vincristine (PCV) chemotherapy versus surgery plus RT alone.
  • Neither study observed a survival benefit with the addition of early PCV chemotherapy.
  • However, both studies found a statistically significant increase in PFS associated with the administration of PCV chemotherapy before surgery or after surgery and RT, with the benefit ranging from 10 to 11 months.
  • The predictive value of 1p and 19q co-deletions is less clear with one study observing a longer PFS with chemotherapy, while the other study did not.
  • AUTHORS' CONCLUSIONS: Early PCV chemotherapy in addition to standard treatment of surgery and RT does not improve OS in patients with AO or AOA.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2014;5:CD007104 [24833028.001]
  • (PMID = 18425979.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 11
  •  go-up   go-down


23. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsey DA, Nimer SD, DeAngelis LM, Cairncross JG: High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neurooncol; 2003 Nov;65(2):127-34
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.
  • PATIENTS AND METHODS: Sixty-nine patients with a median age of 42 (range: 18-67) and a median Karnofsky Performance Score of 90 (range: 70-100) were enrolled.
  • Sixteen patients had a prior diagnosis of low-grade oligodendroglioma and 16 had mixed oligoastrocytoma pathology.
  • Only patients with demonstrably chemosensitive enhancing tumors or those free of enhancing tumor after surgery and induction therapy were eligible to receive high-dose thiotepa.
  • The transplant regimen was well-tolerated; median hospital stay was 20 days (range: 7-43) with a median time to ANC and platelet engraftment of 10 days.
  • Thirty patients (43%) did not receive high-dose thiotepa because of stable or progressive disease (n = 21), excessive toxicity (n = 4), refusal of further therapy (n = 2), failure to obtain insurance coverage (n = 2), or other (n = 1).
  • No treatment-related or long-term neurotoxicity was seen in the transplanted patients.
  • CONCLUSIONS: High-dose chemotherapy with stem cell rescue as initial treatment for anaplastic oligodendroglioma is feasible and associated with prolonged tumor control in some patients.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Hematopoietic Stem Cell Transplantation. Oligodendroglioma / drug therapy. Thiotepa / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Female. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Prognosis. Prospective Studies. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Neurology. 1996 Jan;46(1):203-7 [8559376.001]
  • [Cites] J Clin Oncol. 1997 Dec;15(12):3427-32 [9396393.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):567-73 [7928487.001]
  • [Cites] Med Pediatr Oncol. 1998 Jul;31(1):16-8 [9607424.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):597-601 [8814162.001]
  • [Cites] Neuro Oncol. 2000 Apr;2(2):114-9 [11303620.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]
  • [Cites] J Chronic Dis. 1961 Apr;13:346-53 [13704181.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] Arch Neurol. 1991 Feb;48(2):225-7 [1993014.001]
  • (PMID = 14686732.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa; PCV protocol
  •  go-up   go-down


24. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol; 2003 Dec;14(12):1715-21
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
  • PATIENTS AND METHODS: Thirty patients with histologically verified WHO grade II gliomas (17 astrocytoma, 11 oligodendroglioma, two mixed oligoastrocytoma) following surgery 2-104 months (median 23 months) after initial diagnosis received temozolomide 200 mg/m(2)/day for 5 days, on a 28-day cycle, for a maximum of 12 cycles or until tumour progression.
  • Twenty-four patients received 12 cycles of chemotherapy.
  • Nine patients progressed (three during chemotherapy-one PD and two initial SD-and six after completion of chemotherapy); five had evidence of transformation.
  • On present evidence, temozolomide cannot be considered as primary therapy without formal comparison with other treatment modalities.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2003 Dec;14(12):1695-6 [14630671.001]
  • (PMID = 14630674.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


25. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol; 2001 May 01;19(9):2449-55
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
  • PURPOSE: Most primary oligodendrogliomas and mixed gliomas (oligoastrocytoma) respond to treatment with procarbazine, lomustine, and vincristine (PCV), with response rates of approximately 80%.
  • However, limited data on second-line treatments are available in patients with recurrent tumors.
  • A novel second-generation alkylating agent, temozolomide, has recently demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme and anaplastic astrocytoma.
  • This study describes the effects of temozolomide in patients with recurrent anaplastic oligodendroglioma (AO) and anaplastic mixed oligoastrocytoma (AOA).
  • PATIENTS AND METHODS: Forty-eight patients with histologically confirmed AO or AOA who had received previous PCV chemotherapy were treated with temozolomide (150 to 200 mg/m2/d for 5 days per 28-day cycle).
  • Secondary end points included progression-free survival (PFS), time to progression, overall survival (OS), safety, and tolerability.
  • For the entire treatment group, median PFS was 6.7 months and median OS was 10 months.
  • Twelve patients developed grade 1/2 thrombocytopenia and three patients developed grade 3/4 thrombocytopenia.
  • CONCLUSION: Temozolomide is safe and effective in the treatment of recurrent AO and AOA.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Oligodendroglioma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11331324.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


26. Rushing EJ, Thompson LD, Mena H: Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy. Ann Diagn Pathol; 2003 Aug;7(4):240-4
Hazardous Substances Data Bank. LOMUSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy.
  • We describe a case of anaplastic astrocytoma in a 14-year-old boy arising at the site of a dysembryoplastic neuroepithelial tumor (DNT) 3 years after combined radiation and chemotherapy.
  • The subtotally excised superficial right temporoparietal tumor was originally diagnosed as mixed oligoastrocytoma in 1974; the patient was treated with radiation therapy postoperatively.
  • Postoperatively, he received a 6-week course of chemotherapy (lovustine, CCNU).
  • The specimen from the third surgery showed an anaplastic astrocytoma (Ki-67 up to 12%) and morphologic features characteristic of radiation effect.
  • This is the first documented case of malignant transformation of DNT following radiation and adjuvant chemotherapy.
  • The implications of malignant transformation in subtotally excised complex DNTs and the intriguing issue of the contribution of radiation/chemotherapy are discussed.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Neoplasms, Neuroepithelial / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents, Alkylating / therapeutic use. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Craniotomy. Fatal Outcome. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Lomustine / therapeutic use. Male

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12913847.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


27. Taal W, van der Rijt CD, Sillevis Smitt PA, Kros JM, van Heuvel I, Enting RH, van den Bent MJ: [Favourable result for temozolomide in recurrent high-grade glioma]. Ned Tijdschr Geneeskd; 2005 Jun 18;149(25):1393-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the results of the treatment of recurrent glioma with temozolomide.
  • METHOD: This study evaluated 77 patients with a recurrent high-grade glioma who from August 1997-December 2003 were treated with temozolomide (150-200 mg/m2/day for 5 days per 28-day cycle) following surgery and radiotherapy at the Daniel den Hoed Oncology Centre of the Erasmus MC, Rotterdam, the Netherlands.
  • The patients were divided into 4 groups depending on histology and chemotherapy history.
  • RESULTS: 15 patients received temozolomide for a recurrent anaplastic oligodendroglioma or mixed oligo-astrocytoma.
  • 35 patients underwent second-line chemotherapy with temozolomide after earlier chemotherapy with procarbazine, lomustine and vincristine for recurrent anaplastic oligodendroglioma or mixed oligo-astrocytoma.
  • 14 patients were treated with temozolomide for a recurrent anaplastic astrocytoma with a response of 35% and after 12 months in 8% of these patients there was no disease progression.
  • Of the 13 patients with a recurrent glioblastoma who were treated with temozolomide 16% responded and after 6 and 12 months 21% were still free from progression.
  • CONCLUSION. Temozolomide has an acceptable safety profile and may be regarded as the preferred treatment for recurrent anaplastic gliomas after radiotherapy.
  • There is only a limited role for temozolomide in the treatment of recurrent glioblastoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1376-8 [15997689.001]
  • (PMID = 15997692.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


28. Burton EC, Prados MD: Malignant gliomas. Curr Treat Options Oncol; 2000 Dec;1(5):459-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In adults, the most frequently encountered of these are high-grade or malignant neoplasms of astrocytic and oligodendrocytic lineage, ie, anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), and anaplastic oligodendroglioma (AO), respectively.
  • Tumors of mixed lineage are also seen, the most common of which is designated anaplastic oligoastrocytoma (AOA).
  • Standard treatment for these tumors is typically surgery, followed by radiation then chemotherapy.
  • Surgery is required for a definitive histopathologic diagnosis, which in turn will dictate subsequent therapy options.
  • In almost all cases, surgery is followed by radiation therapy.
  • Postsurgical irradiation is the most effective treatment currently available for improving survival.
  • Radiosurgery and brachytherapy are therapies often used to treat eligible patients at this institution.
  • Adjuvant chemotherapy, conventionally given after radiation, may offer a modest survival benefit in some patients with GBM.
  • Bischloroethylnitrosourea (BCNU) is the typical first-line agent used, but chemotherapy seems to be most beneficial in young patients, with little if any impact on survival for patients over 60 years old.
  • At this institution, we often defer treatment with adjuvant chemotherapy for elderly patients with GBM due to lack of efficacy and the attendant risk with chemotherapy.
  • For anaplastic astrocytomas, oligodendrogliomas, and oligoastrocytomas, a commonly accepted standard is adjuvant chemotherapy following irradiation with the three-drug regimen--procarbazine, CCNU, and vincristine (PCV).
  • However, recent data suggest that treatment with either PCV or BCNU may be appropriate.
  • Patients with this molecular pattern have an exceptional responsiveness to PCV chemotherapy and have prolonged survival.
  • Currently, trials are being conducted to confirm this finding and to determine the best treatment regimen for these patients, with particular regard to the timing of radiation and chemotherapy.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Female. Humans. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1998 Apr;42(4):709-20; discussion 720-3 [9574634.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1379-85 [1325539.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] J Neurosurg. 1993 May;78(5):767-75 [8468607.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):319-26; discussion 326-8 [10690720.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1005-11 [9719109.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Oct;20(9):1642-6 [10543634.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neurooncol. 1999 May;42(3):233-45 [10433107.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1123-8; discussion 1128-30 [10807244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):687-92 [10524423.001]
  • [Cites] J Neurooncol. 1999 May;42(3):247-58 [10433108.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] Neurosurgery. 1997 Nov;41(5):1028-36; discussion 1036-8 [9361056.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4 [7731507.001]
  • [Cites] Neurosurgery. 1999 Jul;45(1):17-22; discussion 22-3 [10414561.001]
  • [Cites] J Neurooncol. 1995 Nov;26(2):111-23 [8787853.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):306-18 [10690719.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Radiology. 2000 Apr;215(1):221-8 [10751490.001]
  • [Cites] Ann Med. 2000 Feb;32(1):81-5 [10711581.001]
  • [Cites] Nat Med. 1996 Mar;2(3):323-5 [8612232.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1112-20; discussion 1120-2 [10807243.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):72-7 [10413158.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] J Natl Cancer Inst. 1990 Dec 19;82(24):1918-21 [2250312.001]
  • (PMID = 12057153.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA09291; United States / NCI NIH HHS / CA / CA13525
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 31
  •  go-up   go-down


29. Bélanger K, MacDonald D, Cairncross G, Gertler S, Forsyth P, Burdette-Radoux S, Bergeron J, Soulières D, Ludwin S, Wainman N, Eisenhauer E: A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. Invest New Drugs; 2003 Nov;21(4):473-80
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma.
  • To determine the efficacy and toxicity of a novel chemotherapeutic approach with topotecan, a camptothecin analog, for progressive or recurring anaplastic oligodendroglioma or mixed oligoastrocytoma.Patients from seven centers with recurrent or progressive disease were treated with topotecan, 1.5 mg/m(2) intravenously (i.v.
  • Topotecan did not demonstrate, with this small sample size, efficacy as a salvage chemotherapy monotherapy after exposure to procarbazine, CCNU and vincristine.
  • [MeSH-major] Astrocytoma / drug therapy. Oligodendroglioma / drug therapy. Topotecan / administration & dosage


30. Schomas DA, Laack NN, Brown PD: Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer; 2009 Sep 1;115(17):3969-78
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 314 patients initially identified, 32 were aged at least 55 years, with a median age at diagnosis of 61 years (range, 55-74 years).
  • Operative pathologic diagnoses comprised astrocytoma (n = 22, 69%), mixed oligoastrocytoma (n = 7, 22%), and oligodendroglioma (n = 3, 9%).
  • Postoperative radiotherapy or chemotherapy was given to 23 (72%) patients and 1 (3%) patient, respectively.
  • Factors adversely affecting OS on univariate analysis were enhancement on computed tomography (P < .001) and supratentorial location (P = .03).
  • Aggressive management with maximally safe resection followed by adjuvant therapy should be strongly considered.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7 [9598670.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3129-40 [9294476.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1227-33 [15690327.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2372-7 [15800329.001]
  • [Cites] Lancet. 2005 Sep 17-23;366(9490):985-90 [16168780.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Neurology. 2007 May 22;68(21):1831-6 [17515545.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):308-13 [17598823.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1338-45 [18323558.001]
  • [Cites] Neurosurgery. 2008 Oct;63(4):700-7; author reply 707-8 [18981880.001]
  • [Cites] J Neurooncol. 2008 Dec;90(3):341-50 [18682893.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):437-45 [19018039.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]
  • [Cites] J Neurosurg. 2000 Jun;92(6):983-90 [10839259.001]
  • [Cites] Strahlenther Onkol. 2000 Jun;176(6):259-64 [10897252.001]
  • [Cites] Neurology. 2001 Mar 13;56(5):618-23 [11245713.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):305-12 [12892238.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):117-25 [15093907.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Cancer. 1975 Nov;36(5):1681-9 [172217.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):649-52 [6164465.001]
  • [Cites] Br J Clin Pharmacol. 1982 Sep;14(3):325-31 [6751362.001]
  • [Cites] J Neurosurg. 1984 Oct;61(4):665-73 [6470776.001]
  • [Cites] Neurosurgery. 1987 Jun;20(6):975-82 [3614580.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):837-41 [3141317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):663-8 [2921165.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]
  • [Cites] Neurosurgery. 1989 May;24(5):686-92 [2716976.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):487-93 [2552044.001]
  • [Cites] Arch Neurol. 1989 Nov;46(11):1238-9 [2818260.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1351-6 [2689399.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] Ann Neurol. 1992 Apr;31(4):431-6 [1586143.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):554-9 [8474646.001]
  • [Cites] W V Med J. 1993 Mar;89(3):102-5 [8475621.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 May 20;26(2):239-44 [8387988.001]
  • [Cites] Acta Neurochir (Wien). 1993;123(1-2):1-7 [8213272.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1093-112 [7677836.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]
  • [Cites] J Neurooncol. 1997 Feb;31(3):273-8 [9049856.001]
  • [Cites] Surg Neurol. 1995 Sep;44(3):208-21; discussion 221-3 [8545771.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):173-7 [8699240.001]
  • [Cites] Neurosurgery. 1996 May;38(5):872-8; discussion 878-9 [8727811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] Neurology. 1999 Mar 10;52(4):867-9 [10078745.001]
  • (PMID = 19536875.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024150; None / None / / UL1 RR024150-01; United States / NCRR NIH HHS / RR / 1 UL1 RR024150-01; United States / NCRR NIH HHS / RR / UL1 RR024150-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS140676; NLM/ PMC2789453
  •  go-up   go-down


31. Chang HT, Cuison RV, Gera R, Saah E, Scott-Emuakpor A, Abood C: 6-year-old girl with hydrocephalus. Brain Pathol; 2009 Oct;19(4):725-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a tectal glioma in a 6-years-old girl with histological features of anaplastic mixed oligoastrocytoma that continues to progress despite chemotherapy and radiation therapy.

  • Genetic Alliance. consumer health - Hydrocephalus.
  • MedlinePlus Health Information. consumer health - Hydrocephalus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744043.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


32. Sipos L, Vitanovics D, Afra D: [Treatment of recidive malignant gliomas with temozolomide]. Orv Hetil; 2002 May 26;143(21):1201-4
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of recidive malignant gliomas with temozolomide].
  • In case of recurrencies reoperation is rarely possible and chemotherapy is the last treatment modality.
  • The treatment had to be stopped in four cases.
  • The mean progress free interval was 6.25 and the mean survival time 9 months.
  • According to the primary histology the mean survival time for glioblastoma patients was 6.8 and for anaplastic astrocytoma or mixed oligoastrocytoma patients 12.2 months.
  • CONCLUSIONS: Due to its low toxicity and relatively long survival time after recurrency temozolomide seems to be a promising drug in the treatment of recurrent malignant gliomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / therapeutic use. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12073541.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


33. Hyder DJ, Sung L, Pollack IF, Gilles FH, Yates AJ, Davis RL, Boyett JM, Finlay JL: Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J Neurooncol; 2007 May;83(1):1-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience.
  • PURPOSE: To review interpathologist diagnosis variability and survival of children treated for either anaplastic mixed glioma (AMG) or anaplastic oligodendroglioma (AO) with surgery, irradiation and chemotherapy.
  • PATIENTS AND METHODS: Two hundred and fifty patients with an institutional diagnosis of malignant glioma were enrolled on Children's Cancer Group CCG-945 between 1985 and 1991, and administered vincristine during involved field radiotherapy, then six cycles of prednisone, lomustine and, vincristine; or two cycles of "eight-drugs-in-one-day" (8-in-1) chemotherapy then involved-field radiotherapy followed by six cycles of 8-in-1 chemotherapy.
  • However, central review established that only nine of 26 children had AMG: either mixed oligoastrocytoma (MOA) or anaplastic mixed oligoastrocytoma (AOA) and only one had AO.
  • CONCLUSION: Diagnosis of these tumors is challenging, with only 35% of institutional diagnoses confirmed for AMG and 25% for AO, and survival among children with these tumors is poor, despite intensive therapy.
  • This suggests reliable diagnostic markers and new therapeutic approaches are needed.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy. Oligodendroglioma / diagnosis. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Child. Child, Preschool. Cohort Studies. Drug Therapy. Female. Humans. Infant. Male. Neurosurgical Procedures. Radiotherapy. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / therapy. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] Hepatology. 1991 Nov;14(5):751-5 [1937381.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):786-8 [10603023.001]
  • [Cites] J Neurooncol. 1994;21(3):255-65 [7699420.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):251-5 [12525516.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] J Neurooncol. 2003 May;63(1):49-54 [12814254.001]
  • [Cites] J Chronic Dis. 1967 Aug;20(8):637-48 [4860352.001]
  • [Cites] J Neurooncol. 1988;6(1):9-23 [3294353.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):197-207 [12816726.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5 [12015841.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Pediatr Neurosurg. 2003 Sep;39(3):114-21 [12876389.001]
  • [Cites] Curr Treat Options Oncol. 2000 Dec;1(5):459-68 [12057153.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Nov;53(6):559-71 [7964897.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3 Suppl 2:S120-3 [2231292.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] J Neurosurg. 1998 Feb;88(2):215-20 [9452226.001]
  • (PMID = 17252186.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


34. van den Bent MJ: Advances in the biology and treatment of oligodendrogliomas. Curr Opin Neurol; 2004 Dec;17(6):675-80
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the biology and treatment of oligodendrogliomas.
  • PURPOSE OF REVIEW: The sensitivity of oligodendroglioma to chemotherapy and the prognostic significance of combined loss of 1p/19q in these tumors are now well established.
  • This review discusses recent molecular, genetic and clinical advances made in studies on oligodendroglioma and mixed oligoastrocytoma.
  • On MRI imaging, OD with combined 1p/19q loss has typical characteristics, including indistinct borders and a mixed signal intensity on T2-weighted images.
  • Despite the large increase in knowledge on the molecular abnormalities in OD, the therapeutic options for these tumors have not improved significantly since the introduction of temozolomide.
  • The increased survival after chemotherapy has been clearly established, but the timing of chemotherapy seems less critical.
  • It is clear that temozolomide is a good alternative to procarbazine, CCNU and vincristine (PCV) chemotherapy, in particular, because it is better tolerated.
  • No randomized trials, however, have compared PCV-chemotherapy to temozolomide.
  • New agents--and probably more targeted therapies--are needed to further improve treatment.
  • SUMMARY: The progress in the understanding of genetic and molecular abnormalities of OD has improved the recognition of treatment-sensitive OD, although this has not yet been mirrored in improved therapies or new treatment options.
  • While chemotherapy improves the outcome of OD, further improvements will likely require new drugs or new treatment concepts.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Oligodendroglioma / drug therapy. Oligodendroglioma / genetics
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Chromosome Aberrations. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Gene Expression Regulation, Neoplastic / genetics. Humans. Radiotherapy / methods. Radiotherapy / trends

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15542975.001).
  • [ISSN] 1350-7540
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 47
  •  go-up   go-down


35. Hiremath GK, Bingaman WE, Prayson RA, Nair D: Oligoastrocytoma presenting with intractable epilepsy. Epileptic Disord; 2007 Sep;9(3):315-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligoastrocytoma presenting with intractable epilepsy.
  • OBJECTIVE: Oligoastrocytomas (OA) are mixed gliomas with distinct oligodendroglial and astrocytic neoplastic components.
  • Median length of refractory epilepsy prior to surgery was 10.5 years (range 1-28 years), and the median number of antiepileptic drugs used was 2 (range 1-10).
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Epilepsy / drug therapy. Epilepsy / etiology
  • [MeSH-minor] Adolescent. Adult. Anticonvulsants / therapeutic use. Craniotomy. Drug Resistance. Epilepsy, Complex Partial / etiology. Epilepsy, Complex Partial / surgery. Female. Humans. Magnetic Resonance Imaging. Male. Memory / physiology. Neoplasm Recurrence, Local. Neurosurgical Procedures. Temporal Lobe / pathology. Temporal Lobe / surgery

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884756.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


36. Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK: Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery; 2007 Nov;61(5):1031-7; discussion 1037-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
  • This study assessed the safety of CB administered by convection-enhanced delivery followed by standard external beam radiation therapy (EBRT) with or without temozolomide (Temodar; Schering-Plough, Kenilworth, NJ) in patients with newly diagnosed malignant gliomas.
  • Safety was assessed during an 11-week observation period after catheter placement RESULTS: Twenty-two patients (12 men, 10 women; median age, 55 yr; 21 with glioblastoma multiforme and one with an anaplastic mixed oligoastrocytoma) were enrolled.
  • Six patients in the final cohort (0.5 microg/mL CB + EBRT + temozolomide [n = 10]) completed treatment, and one patient experienced a dose-limiting toxicity (Grade 3 aphasia and confusion).
  • Four patients were not considered evaluable for a dose decision and were replaced.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Exotoxins / administration & dosage. Exotoxins / adverse effects. Glioma / drug therapy. Glioma / radiotherapy. Interleukin-13 / administration & dosage. Interleukin-13 / adverse effects
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Chemotherapy, Adjuvant / methods. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Dose-Response Relationship, Drug. Drug Delivery Systems / methods. Female. Humans. Infusions, Intralesional / methods. Male. Middle Aged. Nervous System Diseases / chemically induced. Radiotherapy, Conformal. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091279.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 2P50-NS20023; United States / NCRR NIH HHS / RR / K23 RR16065; United States / NCI NIH HHS / CA / R01 CA097611
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Interleukin-13; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


37. Wu SX, Deng ML, Li QQ, Zhao C, Lu TX, Li FY, Cui NJ: [Prognostic analysis of patients with cerebral glioma treated with radiotherapy]. Ai Zheng; 2004 Nov;23(11 Suppl):1561-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Surgery is the major treatment for glioma, and radiotherapy is often needed after operation.
  • METHODS: Records of 158 patients with cerebral glioma, including 123 patients with astrocytoma (AC), 12 patients with oligodendroglioma (OD) or mixed oligoastrocytoma (OA), and 23 patients with glioblastoma multiforme (GBM), received radiotherapy in our center were analyzed.
  • Median radiation dose was 58 Gy (36-75 Gy).
  • Median waiting time from operation to radiotherapy was 29 days (12-261 days).
  • Sixty-eight patients received chemotherapy before or after radiotherapy.
  • Univariate analysis showed that histologic grade (I/II vs. II/IV), histologic type (AC/OD vs. GBM), Karnofsky performance state (KPS) before radiotherapy (>/=80 vs.< 80), extent of resection (total vs non-total), and age(</=40 years vs. >40 years) were significant predictors in association with overall survival rate of patients with glioma.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Radiotherapy, High-Energy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Cobalt Radioisotopes / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Particle Accelerators. Postoperative Care. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15566680.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


38. Cowell JK, Barnett GH, Nowak NJ: Characterization of the 1p/19q chromosomal loss in oligodendrogliomas using comparative genomic hybridization arrays (CGHa). J Neuropathol Exp Neurol; 2004 Feb;63(2):151-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Loss of genetic material from the short arm of chromosome 1 and the long arm of chromosome 19 in anaplastic oligodendrogliomas has been shown to predict responsiveness to chemotherapy.
  • This analysis is highly focused and carried out on a locus-by-locus basis and gives no indication of the extent of other genetic changes occurring in the tumor cells, which may be important in future studies to explore genetic heterogeneity in the response to treatment.
  • Using this approach we have clearly shown that 1p/19q loss in these cases, when compared with microsatellite-mediated detection of loss of heterozygosity, is due to physical hemizygous deletion of the whole chromosome arms in all cases.
  • From our survey of 14 tumors consisting of low-grade oligodendrogliomas (n = 6), anaplastic oligodendrogliomas (n = 5), or mixed oligoastrocytoma (n = 3).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14989601.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA76457; United States / NCI NIH HHS / CA / P30 CA 16056-26
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement